{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fskinandjointspodcast.simplecast.com%2Fepisodes%2Faad2026ltejak-tyk_4q1c","width":444,"version":"1.0","type":"rich","title":"AAD 2026: If They Get There, Do They Stay There? A 140-Week AD JAK Data Dive ","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/017450d4-6458-4a10-9297-ca289770dc2d/14adac00-7ea6-41a0-bfc6-d1cbdf0e899d/news6.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"","height":200,"description":"🎙️ If They Get There, Do They Stay There? A 140-Week AD Data Dive — Part 1 of a 2-Part Double Header\n\nGuests: Dr. Marissa Joseph and Dr. Fiona LovegroveLocation: 📍 AAD 2026\n\nWe came to Denver for AAD 2026, adjusted to the altitude, caught our breath — barely — and dove straight into the data.\n\nIn Part 1 of this two-part atopic dermatitis double header, Dr. Marissa Joseph and Dr. Fiona Lovegrove join us live from the Mile High City to break down fresh new clinical data in moderate-to-severe atopic dermatitis, with a focus on long-term maintenance of stringent patient-reported outcomes with upadacitinib from the Measure Up 1 and Measure Up 2 studies.\n\nBecause patients do not walk into clinic asking if their EASI score improved by 70%.They ask:\n\n“Will I sleep?”“Will the itch stop?”“Can I focus at work or school?”“Can I stop thinking about my eczema every single day?”\n\nOur conversation gets into the so what behind the numbers —what this data implies for your real world patient decisions, why durability matters, why week 16 response may help guide long-term expectations, and why patient-reported outcomes are moving from nice-to-have to true treatment targets in atopic dermatitis.\n\nWe also explore the challenge of measuring multiple domains in practice, and why aiming high does not mean treating partial responders as failures. How do our experts frame better sleep, less itch, and fewer daily disease interruptions for these partial responders?\n\nThink of this as your compact AAD post-game analysis — but instead of Shaq and the scoreboard, we’re breaking down itch, sleep, emotional burden, dose optimization, and the future of treat-to-target AD care.\n\nLearning Objectives:By the end of this episode, listeners will be able to:\n\nDescribe the clinical relevance of long-term patient-reported outcome data in moderate-to-severe atopic dermatitis. \nDiscuss how itch, sleep, emotional burden, and daily functioning can inform treatment success beyond skin clearance alone. \nInterpret the significance of sustained responses from week 16 through longer-term follow-up in the Measure Up 1 and 2 studies. \nIdentify practical considerations and limitations when incorporating stringent PRO targets into real-world dermatology practice. \nApply key insights from AAD 2026 data to therapeutic decision making, patient counselling, expectation-setting, and shared decision-making in AD care. \n\nSkin and Joints Podcast — where we bring the science, the clinical translation, and just enough altitude-related commentary to keep things interesting.\n\nPart 2 is already warming up in the bullpen.\n\n\n\nREFERENCES: \n\nLong-Term Maintenance of Stringent Patient-Reported Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Measure Up 1 and 2 Phase 3 Studies\n\n\n\n#SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #EczemaCare #Dermatology #PatientReportedOutcomes #JAKInhibitors #Upadacitinib #MeasureUp #DermatologyEducation #MedicalEducation #HCPeducation #TreatToTarget #InflammatorySkinDisease #ClinicalData #DermTwitter #MedEd #Vodcast #PodcastEpisode #AADDenver #JAK #JAKinhibitor\n\n\n\nSupported by an IME Grant from ABBVIE.."}